What We Do
At Sandoz our work is focused on improving access to medicines, access to medical information and access to medical capacity building.
Patients and Caregivers
We recognize the importance of patients and caregivers understanding what they can expect from us.
A once-in-a-career opportunity to become a founder of a new Sandoz! Join Us!
Sandoz investing to increase production of much-needed antibiotics
Sandoz is pushing ahead with its capacity expansion program for much-needed antibiotic medicines. As shown in the photo, construction of a new USD 50m plant, announced in November 2022, is already well underway. Our Kundl site in Austria will also manufacture antibiotics for children (pediatric formulations). In total, the company is investing USD 250m to expand its antibiotic manufacturing capabilities in Europe. This has already led to a double-digit increase in capacity in 2022 and another double-digit increase is planned for 2023.
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors
Products & Services
At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine.
We are a pioneer and a global leader in biosimilars with over a decade of experience.